(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 November 2009 (26.11.2009)

PCT

(10) International Publication Number
WO 2009/143523 A1

(51) International Patent Classification:
C07K 14/715 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2009/045182

(22) International Filing Date:
26 May 2009 (26.05.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/055,500 23 May 2008 (23.05.2008) US

(71) Applicants *(for all designated States except US)*: **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US). **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge CB21 6GH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BLOOM, Laird** [US/US]; 82 Falcon Street, Needham, MA 02492 (US). **GILL, Davinder** [US/US]; 20 Charlotte Drive, Andover, MA 01810 (US). **VUGMEYSTER, Yulia** [US/US]; 37 Riverside Drive, North Reading, MA 01864 (US). **YOUNG, Deborah, A.** [US/US]; 39 Nelson Road, Melrose, MA 02176 (US). **LOWE, David** [GB/GB]; Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **VALGE-ARCHER, Viia** [GB/GB]; Milstein Building, Granta Park, Cambridge CB21 6GH (GB).

(74) Agent: **MOLENDA, Victoria, S.**; Fitzpatrick, Cella, Harper & Scinto, 1290 Avenue of the Americas, New York, NY 10104-3800 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: INTERLEUKIN-21 RECEPTOR BINDING PROTEINS

Figure 1a



(57) **Abstract**: The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

WO 2009/143523 A1